TRENTON, ME--(Marketwire - February 16, 2010) -
Bar Harbor BioTechnology, Inc. (BHB) announced
today that it has entered into a license agreement with Life Technologies.
Under the agreement, BHB will offer contract research services that provide
data collection and analysis based on the StellARray™ and XenoQ™
systems. Researchers in the life sciences field can now contract BHB to run
their Real-Time PCR experiments.
"We wanted to make our expertise in assay design available to all genetic
researchers and provide excellent quality data," stated Robert Phelps, CEO
of Bar Harbor BioTechnology. Researchers would purchase StellARrays™ or
XenoQ™ Assays through their exclusive distributor, Lonza Corporation,
and then contract BHB to perform the Real-Time PCR services.
The data generated in the experiments will be analyzed using the Global
Pattern Recognition™ (GPR) analysis software, which is exclusive to
BHB. "GPR has been instrumental in some rather significant discoveries,"
says Dan Shaffer, VP of Product Development for Bar Harbor BioTechnology.
"We believe there are many laboratories that do not have the resources to
utilize our technology. We wanted to change that and make it easier for all
labs to make use of our systems."
Bar Harbor BioTechnology has expanded the staff of the company to provide
the new services secured in this agreement. "We have been very fortunate to
have fantastic support from the State of Maine and our community. This new
expansion was part of a strategic plan to create new high tech jobs here in
Maine," reported Robert Phelps. "We are very proud that we were in a
position to do just that."
About Bar Harbor BioTechnology, Inc.
Bar Harbor BioTechnology, Inc. is a privately held company founded in 2006
and located in the downeast section of Maine. The company launched its
flagship products, GeneSieve™, StellARray™ and Global Pattern
Recognition™ in 2007. The StellARray™ and XenoQ™ systems are
distributed by Lonza Corporation under an exclusive global distribution
agreement that was created in 2008. The StellARray™ system was recently
used to identify a drug that shows the reversal of Type 1 Diabetes in mouse
For more information, please contact Robert Phelps at:
© 2010 Bar Harbor BioTechnology Inc. All rights reserved.
Bar Harbor BioTechnology Inc. undertakes no obligation to release publicly
the results of any revisions to any forward-looking statement made or
implied in this release, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. Statements in this release should be evaluated